4.7 Meeting Abstract

Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/jco.2008.26.15_suppl.5046

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available